Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739505 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00739505 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT00739505, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This clinical trial studies the safety, tolerability, and pharmacology of asfotase alfa when given to adults with HPP.
Interventions
- BIOLOGICAL Asfotase Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739505
The ClinicalTrials.gov registry entry for NCT00739505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Asfotase Alfa is the first listed.
NCT00739505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739505 about?
NCT00739505 is a clinical study titled "Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)". This clinical trial studies the safety, tolerability, and pharmacology of asfotase alfa when given to adults with HPP.
What is the current status of trial NCT00739505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00739505?
The interventions under investigation include: Asfotase Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00739505?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.